Investigation and analysis on the extended clinical application of new anti-tumor drugs in a city
Objective To promote the rational clinical application of new anti-tumor drugs in medical institutions in a city.Methods The special review results of new anti-tumor drugs in all medical institutions in a city from January 2021 to October 2023 were summarized,the expanded clinical application of new anti-tumor drugs was counted,the evidence of evidence-based medicine was retrieved,and the quality of the evidence was graded and analyzed reasonably.Results A total of 17 000 cases(involving 110 varieties)of clinical application of new anti-tumor drugs in all medical institutions in a city were reviewed.3864 cases(accounting for 22.7％,17 varieties)were used with expanded application(mainly including off-label drug use).In the 3864 cases,181 cases(4.7％)were based on grade 1 evidence of effectiveness,which were recommended for clinical application.3064 cases(79.3％)were based on grade 2 evidence of effectiveness,which were suggested for clinical application.564 cases(14.6％)were based on grade 3 evidence of effectiveness,which could be attempted for clinical application under certain circumstances.55 cases(1.4％)were based on grade 4 evidence of effectiveness,which were not recommended for clinical application.Conclusion The expanded clinical application of new anti-tumor drugs is common,and it is also reasonable and necessary.Medical institutions should formulate systems and procedures to strengthen the management of the use of new anti-tumor drugs and promote its rational clinical application.
New anti-tumor drugsExtended clinical applicationOff-label drug useEvidence of evidence-based medicineManagement measure
国家科技期刊平台
NSTL
万方数据
